ReviewRheumatology and therapy2018
Chikungunya Infection: A Re-emerging Epidemic.
Review in Rheumatology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Maternal Chikungunya virus infection and pregnancy outcomes: a global systematic review and meta-analysis of vertical transmission dynamics and associated morbidity.Emerging microbes & infections · 2026Pooled it
- Epidemiology, seroprevalence, and circulation of Chikungunya virus in Southern Africa (SADC region): A systematic review.PLoS neglected tropical diseases · 2026Pooled it
- An ECSA-lineage chikungunya outbreak in Foshan, China: age-stratified clinical and virological profiles.Emerging microbes & infections · 2026Article
- Article
- Research advances in chikungunya virus: Epidemiology, pathogenesis, and control.One health (Amsterdam, Netherlands) · 2026Review
- Single-cell transcriptomic profiling of the splenic and peripheral immune landscape in rhesus macaques during CHIKV infection.Journal of virus eradication · 2026Article
- Eupatorium perfoliatum Counteracts TNF-α Mediated Pathogenesis in Chikungunya Virus Infection.Applied biochemistry and biotechnology · 2026Article
- Dysregulated T cell responses and inflammatory cytokine profiles in patients with acute chikungunya fever: a study from Guangdong, 2025.Frontiers in cellular and infection microbiology · 2026Article
- Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review.Infection and drug resistance · 2026Review
- Review
- A robust fluorogenic substrate for chikungunya virus protease (nsP2) activity.Protein science : a publication of the Protein Society · 2025Article
- Chikungunya Virus: Unveiling Its Global Impact (2002-2024).Interdisciplinary perspectives on infectious diseases · 2025Review
- The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease.BMJ global health · 2024Article
- From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.Journal of travel medicine · 2024Review
- Nifuroxazide Prevents Chikungunya Virus Infection BothViruses · 2024Article
- Chikungunya fever.Nature reviews. Disease primers · 2023Review
- Maternal and perinatal outcomes during a Chikungunya outbreak in Kassala, eastern Sudan.Archives of gynecology and obstetrics · 2022Article
- Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory.BMC infectious diseases · 2021Article
- Early warning systems (EWSs) for chikungunya, dengue, malaria, yellow fever, and Zika outbreaks: What is the evidence? A scoping review.PLoS neglected tropical diseases · 2021Article
- Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms.The Journal of rheumatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya (CHIK) is an arboviral infection caused by the chikungunya virus. An unusual feature of CHIK is its long periods of quiescence followed by an epidemic of devastating severity that can involve millions of people. Manifestations of CHIK range from a mild self-limiting febrile illness with arthralgia and rash to crippling acute and lingering debilitating arthritis. In about 10-60% of patients, musculoskeletal symptoms may persist for up to 3-5 years. Management is mainly symptomatic, with analgesics, antipyretics and non-steroidal anti-inflammatory agents. Ecological changes together with alterations in the viral genome facilitate the development of newer variants with greater pathogenicity, a matter of great concern. The social and economic burdens to a society as a result of CHIK epidemics have generated a considerable interest in the scientific community to decipher the reasons underlying myriad manifestations and to develop management strategies for tackling the menace of CHIK across the globe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.